Lerisetron is primarily used in the management of nausea and vomiting, particularly those induced by chemotherapy and radiation therapy in cancer patients. It functions as a serotonin 5-HT3 receptor antagonist, blocking the actions of serotonin in the gastrointestinal tract and central nervous system, which helps prevent vomiting signals from reaching the brain. Due to its high selectivity and potency, it is effective in both acute and delayed phases of chemotherapy-induced nausea and vomiting. It is often administered orally or intravenously before the start of cancer treatment and may be combined with other antiemetic agents such as corticosteroids or NK1 receptor antagonists for enhanced efficacy. Its favorable pharmacokinetic profile and low incidence of side effects make it a valuable option in supportive care during oncology treatments.